Anticardiolipin antibodies (ACA) are recently recognized to be enhanced risk of thrombosis including cerebral infarction. However, there are no available data concerning the profile of clinical and laboratory findings in patients without evidence of collagen disease who suffered cerebral infraction with positive ACA. The purpose of this study was to clarify the clinical and laboratory features of these patients. ACA was measured by enzyme linked immunosorbent assay (ELISA) in 72 consecutive patients affected by cerebral infarction without collagen diseases.
Among 72 patients, ACA was positive in 15 (21%), including 9 males and 6 females. These 15 patients had at least one risk factor for cerebral infarction, such as hypertension, diabetes, hyperlipidemia, smoking history, atrial fibrillation, valvular heart disease, but none of them showed thrombocytopenia. The mean age of ACA-positive patients when they had the first attack of stroke was significantly younger than that of ACA-negative patients (55 ± 15 years versus 66 ± 12 years, p<0.05). In 15 ACA-positive patients, 8 (53%) had a history of recurrent cerebral infarcts, and that was more frequent than patients without ACA (13/57, 23%) (p<0.05). Hypertension was rarer in patients with ACA (3/15, 20%) than in those without ACA (37/57, 65%) (p<0.05), while the prevalence of atrial fibrillation and/or valvular heart diseases was significantly higher in ACA-positive patients (8/15, 53%) than in ACA-negative patients (12/57, 20%) (p<0.05). In platelet function tests, platelet factor 4 was significantly higher in patients with ACA than patients without ACA (54.6 ± 32.0 ng/ml versus 22.3 ± 23.6 ng/ml, p<0.05). In the molecular markers of coagulation and fibrinolysis system, D-dimer, fibrinopeptide Bβ
15-42, thrombin-antithrombin III complex were significantly higher in patients with ACA than in controls, but not than in patients without ACA.
In conclusion, the presence of ACA in patients with cerebral infarcts without collagen diseases, is associated with early and/or recurrent onset of cerebral infarction and higher prevalence of heart diseases. Platelet activation was suggested to contribute the pathogenesis of cerebral infarction in ACA-positive patients.
View full abstract